Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 22;23(15):8075. doi: 10.3390/ijms23158075

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Comparison of the antitumor efficacy of the Karanahan approach alone and in combination with intratumoral injections of GcMAF-RF in the model of weakly immunogenic Lewis carcinoma. (A) Therapeutic regimen for treating Lewis carcinoma using the Karanahan approach. (B) Therapeutic regimen for treating Lewis carcinoma using the Karanahan approach in combination with intratumoral injections of GcMAF-RF. Arrows indicate intraperitoneal injections, arrowheads—intratumoral. (C) Changes in tumor growth in the study and control groups. Mean ± SD values are shown. (D) Changes in the number (%) of mice with tumors. (E) Animal survival graph.